Contribution of oral magnetic particles
β
Frank P. BoudghΓ«ne; Torre Bach-Gansmo; Jean-Didier Grange; Samuel Lame; Christin
π
Article
π
1993
π
John Wiley and Sons
π
English
β 688 KB
## Abstract An open phase III clinical trial of the oral contrast agent OMP (oral magnetic particles) was performed in 35 patients undergoing abdominal magnetic resonance (MR) imaging at 1.5 T with axial spinβecho and gradientβecho sequences. The diagnostic efficacy of OMP was examined by comparing